- The appointment of Eric Dobmeier and Natasha Hernday to the
Board brings extensive operational and business development
experience to support corporate and pipeline strategy
- Janux also announced the resignation of Jay Lichter, Ph.D.,
from the Board, and the appointment of current Board member Ronald
W. Barrett, Ph.D., as Chairperson
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a
clinical-stage biopharmaceutical company developing a broad
pipeline of novel immunotherapies by applying its proprietary
technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor
Activated Immunomodulator (TRACIr) platforms, today announced the
appointment of Eric Dobmeier and Natasha Hernday to its Board of
Directors.
“Eric and Natasha’s vast experience and proven leadership in the
biopharmaceutical industry are tremendous assets for Janux at this
pivotal stage of our growth,” said David Campbell, Ph.D., President
and CEO of Janux Therapeutics. “Eric’s extensive experience in
biopharmaceutical operations and strategic growth will be
invaluable as Janux continues to advance its pipeline. Natasha’s
background in corporate strategy and identifying, executing and
managing high-value partnerships will be essential as Janux looks
to expand its opportunities to further its mission in developing
next-generation cancer therapies.”
Dr. Campbell continued, “Their contributions will not only
enhance our strategic direction but ultimately benefit patients
through the potential development of next-generation cancer
therapies. We are excited to welcome them to our Board and look
forward to their contributions.”
Eric Dobmeier, J.D. has more than 20 years of experience
in the biotechnology industry as both an executive and board
member. Most recently, he was the President and CEO of Chinook
Therapeutics, where he led the company through multiple strategic
growth initiatives ultimately leading to its acquisition by
Novartis in 2023 for $3.5 billion. Prior to Chinook, Mr. Dobmeier
spent 16 years in a series of positions of increasing
responsibility at Seattle Genetics, including Chief Operating
Officer, during the company’s growth from 60 to 1,200 employees,
from a market cap of $150 million to over $8 billion and through
its transition to a commercial company with FDA approval and launch
of Adcetris, a novel lymphoma drug. During his career, Mr. Dobmeier
has been directly involved in raising more than $2 billion in
equity capital and led negotiation of many corporate alliances with
leading biotechnology and pharmaceutical companies. He is currently
a venture partner at Samsara Biocapital and serves on the boards of
directors of Structure Therapeutics and Abdera Therapeutics.
Natasha Hernday previously served as Chief Business
Officer and a member of the Executive Committee at Seagen Inc.
(formerly Seattle Genetics) and was pivotal in driving business
development, including alliance management, strategic partnerships,
mergers, and acquisitions. Ms. Hernday led the acquisition of
Cascadian Therapeutics in 2018 for approximately $614 million and a
global strategic oncology collaboration with Merck in 2020 for over
$1.5 billion in upfront cash and equity. Cascadian’s lead asset has
since been approved and is achieving over $400 million in yearly
revenue. Ms. Hernday’s strategic insight and successful track
record in transactions culminated in Seagen's acquisition by Pfizer
in 2023 for $43 billion. Prior to her role at Seagen, Ms. Hernday
spent 16 years at Amgen, where she began her career in discovery
research, then held various leadership positions in corporate
development and corporate strategy, including as Director, Mergers
& Acquisitions and as Director, Out-Partnering, playing a key
role in numerous high-value transactions. Additionally, Ms. Hernday
served on the Board of Alpine Immune Sciences, which was acquired
by Vertex Pharmaceuticals in 2024 for $4.9 billion.
In addition, Janux announced the resignation of Jay Lichter,
Ph.D., from the Board of Directors. Dr. Lichter, a key figure as
the head of Janux’s founding seed investor Avalon Ventures, has
been instrumental in the company’s growth and success. Current
Board member Ronald W. Barrett, Ph.D., will replace Jay Lichter as
Chairperson of the Board.
“We deeply appreciate Jay’s leadership and dedication over the
years,” said Dr. Campbell. “His vision and commitment have been
integral to our achievements, and for that, we thank him deeply.
Ron’s extensive experience and leadership in the biopharmaceutical
industry will be vital as Janux continues to advance its innovative
pipeline, and I look forward to his continued stewardship and
contributions.”
Janux’s TRACTr and TRACIr Pipeline
Janux’s first clinical candidate, JANX007, is a TRACTr that
targets PSMA and is being investigated in a Phase 1 clinical trial
in adult subjects with metastatic castration-resistant prostate
cancer (mCRPC). Janux’s second clinical candidate, JANX008, is a
TRACTr that targets EGFR and is being studied in a Phase 1 clinical
trial for the treatment of multiple solid cancers including
colorectal cancer, squamous cell carcinoma of the head and neck,
non-small cell lung cancer, and renal cell carcinoma. We are also
generating a number of additional TRACTr and TRACIr programs for
potential future development, some of which are at development
candidate stage or later. We are currently assessing priorities in
our preclinical pipeline.
About Janux Therapeutics
Janux is a clinical-stage biopharmaceutical company developing
tumor-activated immunotherapies for cancer. Janux’s proprietary
technology enabled the development of two distinct bispecific
platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor
Activated Immunomodulators (TRACIr). The goal of both platforms is
to provide cancer patients with safe and effective therapeutics
that direct and guide their immune system to eradicate tumors while
minimizing safety concerns. Janux is currently developing a broad
pipeline of TRACTr and TRACIr therapeutics directed at several
targets to treat solid tumors. Janux has two TRACTr therapeutic
candidates in clinical trials, the first targeting PSMA is in
development for prostate cancer, and the second targeting EGFR is
being developed for colorectal, lung, head and neck, and renal
cancers. For more information, please visit www.januxrx.com and
follow us on LinkedIn.
Forward-Looking Statements
This news release contains certain forward-looking statements
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Such forward-looking statements include statements
regarding, among other things, Janux’s ability to bring new
treatments to cancer patients in need, expectations regarding the
timing, scope and results of Janux’s development activities,
including its ongoing and planned preclinical studies and clinical
trials, the potential benefits of Janux’s product candidates and
platform technologies and expectations regarding the use of Janux’s
platform technologies to generate novel product candidates. Factors
that may cause actual results to differ materially include the risk
that compounds that appear promising in early research do not
demonstrate safety and/or efficacy in later preclinical studies or
clinical trials, the risk that Janux may not obtain approval to
market its product candidates, uncertainties associated with
performing clinical trials, regulatory filings and applications,
risks associated with reliance on third parties to successfully
conduct clinical trials, the risks associated with reliance on
outside financing to meet capital requirements, and other risks
associated with the process of discovering, developing and
commercializing drugs that are safe and effective for use as human
therapeutics, and in the endeavor of building a business around
such drugs. You are urged to consider statements that include the
words “may,” “will,” “would,” “could,” “should,” “believes,”
“estimates,” “projects,” “promise,” “potential,” “expects,”
“plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,”
or the negative of those words or other comparable words to be
uncertain and forward-looking. For a further list and description
of the risks and uncertainties Janux faces, please refer to Janux’s
periodic and other filings with the Securities and Exchange
Commission, which are available at www.sec.gov. Such
forward-looking statements are current only as of the date they are
made, and Janux assumes no obligation to update any forward-looking
statements, whether as a result of new information, future events
or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240722549490/en/
Investors: Andy Meyer Janux Therapeutics
ameyer@januxrx.com (202) 215-2579
Media: Jessica Yingling, Ph.D. Little Dog Communications
Inc. jessica@litldog.com (858) 344-8091
Janux Therapeutics (NASDAQ:JANX)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Janux Therapeutics (NASDAQ:JANX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
